title: A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.
abstract: BACKGROUND
  Hereditary angioedema (HAE) is a congenital disorder with recurrent attacks of localized swelling of submucosal tissue, subcutaneous tissue, or both caused by a deficiency of the plasma protein C1 inhibitor (C1 esterase inhibitor [C1INH]).
  
  
  OBJECTIVE
  We sought to evaluate the effects of recombinant human C1INH (rhC1INH) isolated from the milk of transgenic rabbits in 12 asymptomatic patients with HAE.
  
  
  METHODS
  rhC1INH was intravenously administered at doses of 6.25 to 100 U/kg on 2 occasions.
  
  
  RESULTS
  rhC1INH appeared safe and was well tolerated. The course of functional C1INH in plasma showed a full initial recovery (dose-normalized maximum concentration of about 0.02 U/mL/U/kg) and a dose-dependent clearance of rhC1INH. After infusion of rhC1INH at 100 U/kg, a clearance of approximately 13 mL/min, a half-life of approximately 3 hours, and a volume of distribution of approximately 3 L were observed. Infusion at this dose led to functional C1INH levels in plasma of at least twice the normal level for about 2 hours and greater than 0.4 U/mL for about 9 hours. rhC1INH displayed dose-dependent biologic activity by increasing the C4 level, which was about 2-fold at 12 hours after rhC1INH at 100 U/kg, and decreasing levels of cleaved C4.
  
  
  CONCLUSIONS
  The observed safety profile and biologic activity of rhC1INH warrants further clinical studies to assess its efficacy in treating HAE attacks.
authors.affiliation: Centre for Human Drug Research, Leiden, The Netherlands. mdoorn@chdr.nl
authors.forename: Martijn B A
authors.initials: MB
authors.lastname: van Doorn
authors.forename: Jacobus
authors.initials: J
authors.lastname: Burggraaf
authors.forename: Tijtje
authors.initials: T
authors.lastname: van Dam
authors.forename: Anke
authors.initials: A
authors.lastname: Eerenberg
authors.forename: Marcel
authors.initials: M
authors.lastname: Levi
authors.forename: Cornelis E
authors.initials: CE
authors.lastname: Hack
authors.forename: Rik C
authors.initials: RC
authors.lastname: Schoemaker
authors.forename: Adam F
authors.initials: AF
authors.lastname: Cohen
authors.forename: Jan
authors.initials: J
authors.lastname: Nuijens
mesh_terms: D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D000818:Animals; D030801:Animals, Genetically Modified; D003174:Complement C1 Inactivator Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D050718:Complement C1 Inhibitor Protein; D003181:Complement C4 / Q000378:metabolism; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D015843:Serpins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D003181:Complement C4; D011994:Recombinant Proteins; C469952:SERPING1 protein, human; D015843:Serpins